Loading clinical trials...
Loading clinical trials...
This trial will demonstrate localised uptake of a radiolabelled fungal component (siderophore) in areas of known specific invasive fungal (Aspergillus) infection.
This open label, single centre, proof of concept pilot imaging trial will evaluate technique for the diagnosis of invasive Aspergillus infection. It aims to demonstrate uptake of the gallium-siderophore tracer at sites of known proven/probable invasive aspergillus app infection. It will also assess the safety and tolerability of this technique. 10 patients within 2 weeks of proven or probable invasive fungal infection (IFI) diagnosis will be recruited to this study over a period of 12-24 months.
Age
18 - No limit years
Sex
ALL
Healthy Volunteers
No
Peter MacCallum Cancer Centre
Melbourne, Victoria, Australia
Start Date
December 1, 2023
Primary Completion Date
October 1, 2026
Completion Date
April 1, 2027
Last Updated
September 5, 2025
10
ESTIMATED participants
68Ga-labelled TAFC PET/CT scan
DIAGNOSTIC_TEST
Lead Sponsor
Peter MacCallum Cancer Centre, Australia
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT06640296